Ruxolitinib protects lipopolysaccharide (LPS)-induced sepsis through inhibition of nitric oxide production in mice

BACKGROUND: Ruxolitinib is an inhibitor of Janus kinases (JAK) 1/2. It was authorised recently by the U.S. Food and Drug Administration (FDA) as a new Myelofibrosis treatment. In this study, we identified ruxolitinib as a new inhibitor of nitric oxide (NO) production in response to lipopolysaccharid...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, He, Xingfeng, Wang, Xingtong, Sun, Yu, Wu, Guosheng, Fang, He, Wang, Chen, Luo, Pengfei, Xia, Zhaofan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214887/
https://www.ncbi.nlm.nih.gov/pubmed/32411769
http://dx.doi.org/10.21037/atm-20-2972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214887/
https://www.ncbi.nlm.nih.gov/pubmed/32411769
http://dx.doi.org/10.21037/atm-20-2972

Ejemplares similares